Skip to main content
U.S. flag

An official website of the United States government

Biomarkers: Biomarkers for preclinical/clinical drug development (Milestone 9.A)

In Progress

Timeline Start - End

2016 - 2024

Research Implementation Area


Develop and validate translatable biomarkers for their use in preclinical and clinical drug development. These efforts should include the development of pharmacodynamic biomarkers of target engagement, biomarkers of incipient disease (ocular, olfactory) and biomarkers for detection and tracking of synaptic dysfunction.

Success Criteria

Develop and validate at least 12 translatable biomarkers for use in preclinical and clinical drug development.

Summary of Key Accomplishments

Through the NIA-supported MODEL-AD Centers, researchers are developing translatable biomarkers that can be used in preclinical and clinical drug development. The Centers are developing new mouse models for late-onset AD and are conducting detailed characterization of the most promising models; this includes a collaboration with the Accelerating Medicines Partnership for AD (AMP AD) focused on comparing the molecular signatures from brain and blood samples between the mouse models of late onset AD and people living with AD.

The key accomplishments summary is current as of July 2022. 

Accomplishments/Implementation Activities

Funding Initiatives

Research Programs and Resources

Research Highlights

Relevant Recommendations

Related Milestones

Search all Research Categories

An official website of the National Institutes of Health